Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 + Gecacitinib in advanced NSCLC
NCT06903377Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in non-small cell lung cancer (NSCLC), sponsored by Zelgen. Started May 2025; status: recruiting.
02
Drugs
nilvanstomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06903377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903377.